• Cécile Brouard, Josiane Pillonel, Marjorie Boussac, Victor de Lédinghen, Antoine Rachas, Christine Silvain, Nathalie Lydié, Stéphane Chevaliez, Corinne Pioche, Julien Durand, Florence Lot, and Elisabeth Delarocque-Astagneau.
• Santé publique France, the National Public Health Agency, Saint-Maurice, France. cecile.brouard@santepubliquefrance.fr.
• Bmc Infect Dis. 2020 Oct 15; 20 (1): 759.

BackgroundHepatitis C virus (HCV) elimination by 2030, as targeted by the World Health Organization (WHO), requires that 90% of people with chronic infection be diagnosed and 80% treated. We estimated the cascade of care (CoC) for chronic HCV infection in mainland France in 2011 and 2016, before and after the introduction of direct-acting antivirals (DAAs).MethodsThe numbers of people (1) with chronic HCV infection, (2) aware of their infection, (3) receiving care for HCV and (4) on antiviral treatment, were estimated for 2011 and 2016. Estimates for 1) and 2) were based on modelling studies for 2011 and on a virological sub-study nested in a national cross-sectional survey among the general population for 2016. Estimates for 3) and 4) were made using the National Health Data System.ResultsBetween 2011 and 2016, the number of people with chronic HCV infection decreased by 31%, from 192,700 (95% Credibility interval: 150,900-246,100) to 133,500 (95% Confidence interval: 56,900-312,600). The proportion of people aware of their infection rose from 57.7 to 80.6%. The number of people receiving care for HCV increased by 22.5% (representing 25.7% of those infected in 2016), while the number of people on treatment increased by 24.6% (representing 12.1% of those infected in 2016).ConclusionsThis study suggests that DAAs substantially impact CoC. However, access to care and treatment for infected people remained insufficient in 2016. Updating CoC estimates will help to assess the impact of new measures implemented since 2016 as part of the goal to eliminate HCV.

31 keywords...

hide…